This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AUA 2024
APCCC 2024
EAU 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
2018 International Bladder Cancer Network
Viewing 8-27 of 30 articles
IBCN 2018: Inhibitors of Metabolic Processes in Bladder Cancer Cells
IBCN 2018: Multispectral Imaging Enables Multiparametric Cystoscopy and Transurethral Resection of Bladder Cancer
IBCN 2018: Inhibition of a G9a/EZH2 Network Triggers an Immune-Mediated Bladder Cancer Regression
IBCN 2018: Bladder Cancer and Therapy from an Immunologist's Perspective
IBCN 2018: Lentiviral Interferon: A Novel Method for Gene Therapy in Bladder Cancer
IBCN 2018: Association of Circulating Tumor -DNA Genomic Alterations with Outcomes in Metastatic Urothelial Carcinoma
IBCN 2018: A Non-Invasive Diagnostic Urine Assay to Safely Reduce the Need for Diagnostic Cystoscopy in Patients Presenting with Hematuria
IBCN 2018: STAG2 Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle Invasive Bladder Cancer
IBCN 2018: Insights in the Role of Chemokines in Cancer Metastasization
IBCN 2018: Consensus Molecular Classification of Muscle-Invasive Bladder Cancer
IBCN 2018: Novel Immune Basal Subtypes to Predict Pathologic Response to Chemotherapy and Survival Benefit in Muscle-Invasive Bladder Cancer
IBCN 2018: Combining DNA-Repair Gene Mutations and Molecular Subtyping for More Accurate Prediction of Outcome after Neoadjuvant
IBCN 2018: Signature Immunohistochemical Classifier of Molecular Subtypes in Bladder Cancer
IBCN 2018: A Genomic Classifier for Identifying a Neuroendocrine-like Bladder Cancer Subtype
IBCN 2018: The Impact of Chemotherapy on Immune Microenvironment
IBCN 2018: PPARɣ-Mediated Repression of TFAP2A Expression Identifies an Important Transcriptional Circuit in Basal-Squamous Bladder Cancer
IBCN 2018: Defining the Proteomic Landscape of Non – Muscle Invasive Bladder Cancer
IBCN 2018: MIBC Genomics in and Beyond TCGA and the PanCancerAtlas
IBCN 2018: Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer
IBCN 2018: Genomic and Transcriptomic Heterogeneity in Bladder Cancer - Impact on Clinical Decision Making?
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
